Strategic partnerships Leverage the RainDance acquisition history by targeting Bio-Rad Laboratories and other large CROs as potential partners or distributors to expand global reach and integration of RainDrop and ThunderStorm/ThunderBolts platforms.

Non-invasive focus Position RainDance technologies for oncology and infectious disease research by highlighting non-invasive liquid biopsy capabilities, appealing to cancer centers and research institutions seeking early detection tools and higher-sensitivity assays.

High-throughput opportunities Offer RainDrop Plus enhancements and automated analysis capabilities to labs with throughput bottlenecks, including academic cores and translational research facilities, to drive adoption in high-volume workflows.

Global service reach Emphasize international sales and service network to global customers, targeting regions underrepresented in current distribution, paired with training programs to reduce adoption barriers and shorten time-to-value.

Strategic funding signals Capitalize on substantial funding history and credible performance by reaching out to large genomics players and biopharma collaborators seeking validated, award-winning platforms for assay enrichment and targeted sequencing.